Articles from SpikImm

SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and worldwide license agreement for potent monoclonal antibodies targeting the BK virus. These monoclonal antibodies were developed through the project HuMABK led by Pr. Samira FAFI-KREMER, Director of the Institut de Virologie de Strasbourg and Pr. Pascal POIGNARD, Head of the "Antibodies and Infectious Diseases" research team at the Institut de Biologie Structurale of Grenoble. This agreement reinforces SpikImm's portfolio and expertise for the prophylactic treatment of viral infections in immunocompromised patients. Since the option agreement signed in 2024, SpikImm has already made progress in its preclinical work, and has successfully completed the development of the cell line for GMP manufacturing. The aim is to carry out the first in human studies by 2026.